miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Stock market today: Dow ekes out fresh record, S&P 500, Nasdaq rally for 2nd day as tech bounce back continues

View original at finance.yahoo.com
Stock market today: Dow ekes out fresh record, S&P 500, Nasdaq rally for 2nd day as tech bounce back continues US stocks rose on Monday, continuing a bounce back from a turbulent week that ended with the Dow closing above 50,000 for the first time, as investors face another busy schedule of earnings and economic data…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We believe that a revamped OpenAI will return to its position as Google's top challenger and with a fresh stack of capital be able to live up to its obligations this year, including to Oracle

    80% confidence

  • OpenAI already has as much as $40B of cash on hand and may be raising as much as another $100B by the end of the quarter

    80% confidence

  • As we started 2026, these negative situations have all improved

    80% confidence

  • The current Bitcoin price action is a mere crisis of confidence. Nothing broke, no skeletons will show up

    80% confidence

  • The Bitcoin bear case is the weakest in its history

    80% confidence

  • Our performance in 2025 was negatively affected by persistently weak production levels from the automotive sector throughout the entire year, an expiring five-year slab contract becoming value-destructive during its last year, and a newly adverse dynamic in the Canadian market

    80% confidence

  • We are now more positive on OpenAI, based on changes in strategy, new frontier models, the pressure on Google's competitors from its recent ascent, and progress on its fundraising efforts

    80% confidence

  • Initial negotiations with Iran were very good

    80% confidence

  • Our advanced semiconductor solutions will directly power AWS's next-generation infrastructure, enabling their customers to push the boundaries of AI, high-performance computing, and digital connectivity

    80% confidence

  • In an AI world, Bitcoin and crypto are not interesting enough

    80% confidence

  • This strategic engagement establishes ST as an important supplier to AWS and validates the strength of our innovation, proprietary technology portfolio, and proven manufacturing-at-scale capabilities

    80% confidence

  • Software isn't dead. We believe companies will continue to pay for Oracle's products and that they will not be vibe coded away

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Stock market today: Dow ekes out fresh record, S&P 500, Nasdaq rally for 2nd day as tech bounce back continues — Source | Via News | es.VIA.NEWS